We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of N-Acetylcysteine on Residual Renal Function in Chronic Hemodialysis Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by Assaf-Harofeh Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00507052
First Posted: July 25, 2007
Last Update Posted: July 25, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Assaf-Harofeh Medical Center
  Purpose

In our opinion, it is worth to check an ability of antioxidant therapy to produce a favorable effect on Residual Renal Function.

The aim of our study is to investigate the effect of N-acetylsysteine on RRF in prevalent HD patients.


Condition Intervention
Hemodialysis Renal Failure Drug: N-acetylcysteine

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by NLM:


Further study details as provided by Assaf-Harofeh Medical Center:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with ESRD, treated with chronic hemodialysis

Exclusion Criteria:

  • Patients will be excluded from the study if they are:

    1. Patients with acute renal failure
    2. Currently treated with antioxidants ( NAC, vitamin E ets.)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507052


Contacts
Contact: Leonid S Feldman, MD +972-8-9779383 ext +972 leonidf@asaf.health.gov.il

Locations
Israel
Assaf Harofeh Not yet recruiting
Zerifin, Israel, 70300
Contact: Leonid S Feldman, MD    +972-8-9779383 ext +972    leonidf@asaf.health.gov.il   
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Investigators
Principal Investigator: Leonid S Feldman, MD Assaf Harofeh MC
  More Information

ClinicalTrials.gov Identifier: NCT00507052     History of Changes
Other Study ID Numbers: 346147RRF
First Submitted: July 24, 2007
First Posted: July 25, 2007
Last Update Posted: July 25, 2007
Last Verified: July 2007

Keywords provided by Assaf-Harofeh Medical Center:
Hemodialysis
Residual Renal Function

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Acetylcysteine
N-monoacetylcystine
Antiviral Agents
Anti-Infective Agents
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes